Metodika CEA na příkladu temozolomidu a intratékálně aplikovaného karmustinu u pacientů s glioblastoma multiforme
| Title in English | Methodology of cost-effectiveness analysis (CEA) on the example of temozolomide and intrathecally applied carmustine in patients with glioblastoma multiforme |
|---|---|
| Authors | |
| Year of publication | 2011 |
| Type | Article in Periodical |
| Magazine / Source | Postgraduální medicína |
| MU Faculty or unit | |
| Citation | |
| Field | Oncology and hematology |
| Keywords | cost effectiveness; evaluation; temozolamid; carmustine |
| Description | Cost effectiveness analysis (CEA) is together with cost minimization analysis, cost utility analysis and cost benefit analysis one of the main tools of pharmaco-economics. The main aim of CEA is to quantify and compare costs of two or more treatment alternatives, usually described in monetary units and related to the natural health units, e. g. change of blood pressure, time to disease progression, blood cholesterol level change, quality of life, etc. Methodology of CEA should encompass the appropriate treatment options alternatives, perspective (point of view of e. g. a healthcare provider, healthcare payer, patient or whole society), an assessment of costs as well as appropriate clinical outcomes of all alternatives, change of costs during the assessed period, a sensitivity analysis and description of all limitations including possibility of results generalization. The aim of this article is to describe basic characteristics of CEA and highlight issues that author must face and resolve in the process of carrying out the analysis. |